temocillin

Temocillin is a semisynthetic, narrow-spectrum, beta-lactamase-resistant penicillin antibiotic belonging to the carboxypenicillin subclass. It was originally developed by Beecham and is currently marketed by Eumedica Pharmaceuticals under the brand name Negaban[1][4][5]. Temocillin acts by binding to and inactivating penicillin-binding proteins (PBPs) on the inner membrane of bacterial cell walls, thereby inhibiting peptidoglycan synthesis essential for cell wall strength and rigidity. This leads to bacterial cell lysis and death[3][6]. Its distinguishing feature is resistance to hydrolysis by most beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and AmpC enzymes produced by Gram-negative bacteria such as Enterobacteriaceae[1][7]. Temocillin is primarily indicated for infections caused by multidrug-resistant Gram-negative organisms, especially urinary tract infections (UTIs), sepsis, and respiratory infections due to ESBL or AmpC-producing bacteria. It has little or no activity against Gram-positive bacteria or Pseudomonas aeruginosa[1][4].

Brand names

Negaban

Other names

temocillinatemocillinetemocillinum